指南与共识治疗药物监测与药物基因组学

美国临床实践指南中的药物基因组学检测推荐现状

Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.
指南 / 共识 · Am J Health Syst Pharm · 2024-01-01

本文为叙述性综述,评估美国临床实践指南对21个基因-药物对的药物基因组学检测推荐情况。结果显示提供检测推荐的指南相对较少;HLA-B*57:01与阿巴卡韦、G6PD与拉布立酶的检测推荐跨指南较为一致;CYP2C19-氯吡格雷、CYP2D6-可待因、CYP2D6-曲马多、CYP2B6-依非韦伦、TPMT-硫嘌呤、NUDT15-硫嘌呤等基因-药物对至少有一条指南推荐检测或认为可考虑检测;同一基因-药物对的推荐在不同机构间常不一致,同一机构不同指南间有时亦不一致。

要点

  • 仅少数美国临床实践指南给出药物基因组学检测推荐。
  • HLA-B*57:01-阿巴卡韦与G6PD-拉布立酶检测推荐跨指南较一致。
  • 同一基因-药物对的检测推荐在不同机构及同一机构不同指南间常不一致。

核心结论

  • 美国临床实践指南中药物基因组学检测推荐相对较少,且同一基因-药物对的推荐在不同机构间及同一机构不同指南间常不一致。
  • 采用标准化方法评估药物基因组学检测的临床效用证据,可能提高指南中检测推荐的纳入率与一致性。

研究设计与样本

  • 叙述性综述,评估美国临床实践指南对21个基因-药物对的药物基因组学检测推荐及其在机构内和机构间的一致性。
  • 21个基因-药物对均具有明确的药物反应关联,且均被临床药物基因组学实施联盟(CPIC)列为临床可操作。

主要发现

  • 提供药物基因组学检测推荐的临床实践指南相对较少。
  • HLA-B*57:01检测(阿巴卡韦启用前)与G6PD检测(拉布立酶启用前)的推荐跨指南基本一致,二者均被纳入药品说明书。
  • 至少有一条指南推荐检测或认为可考虑检测的基因-药物对包括CYP2C19-氯吡格雷、CYP2D6-可待因、CYP2D6-曲马多、CYP2B6-依非韦伦、TPMT-硫嘌呤和NUDT15-硫嘌呤。
  • 同一基因-药物对的检测推荐在不同机构间常不一致,同一机构不同指南间有时也不一致。

临床怎么用

  • 查阅美国临床实践指南中药物基因组学检测推荐时,应关注同一基因-药物对在不同机构及同一机构不同指南间的推荐差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment. However, clinical uptake of pharmacogenetic testing has been limited. Clinical practice guidelines recommend biomarker tests that the guideline authors deem to have demonstrated clinical utility, meaning that testing improves treatment outcomes. The objective of this narrative review is to describe the current status of pharmacogenetic testing recommendations within clinical practice guidelines in the US. SUMMARY: Guidelines were reviewed for pharmacogenetic testing recommendations for 21 gene-drug pairs that have well-established drug response associations and all of which are categorized as clinically actionable by the Clinical Pharmacogenetics Implementation Consortium. The degree of consistency within and between organizations in pharmacogenetic testing recommendations was assessed. Relatively few clinical practice guidelines that provide a pharmacogenetic testing recommendation were identified. Testing recommendations for HLA-B*57:01 before initiation of abacavir and G6PD before initiation of rasburicase, both of which are included in drug labeling, were mostly consistent across guidelines. Gene-drug pairs with at least one clinical practice guideline recommending testing or stating that testing could be considered included CYP2C19-clopidogrel, CYP2D6-codeine, CYP2D6-tramadol, CYP2B6-efavirenz, TPMT-thiopurines, and NUDT15-thiopurines. Testing recommendations for the same gene-drug pair were often inconsistent between organizations and sometimes inconsistent between different guidelines from the same organization. CONCLUSION: A standardized approach to evaluating the evidence of clinical utility for pharmacogenetic testing may increase the inclusion and consistency of pharmacogenetic testing recommendations in clinical practice guidelines, which could benefit patients and society by increasing clinical use of pharmacogenetic testing.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Hertz DL, Bousman CA, McLeod HL, et al. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. Am J Health Syst Pharm. 2024. PMID: 38652504. doi:10.1093/ajhp/zxae110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。